The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections

Florian Wagenlehner, Zafer Tandogdu, Riccardo Bartoletti, Tommaso Cai, Mete Cek, Ekaterina Kulchavenya, Béla Köves, Kurt Naber, Tamara Perepanova, Peter Tenke, Björn Wullt, Florian Bogenhard, Truls Erik Bjerklund Johansen, Florian Wagenlehner, Zafer Tandogdu, Riccardo Bartoletti, Tommaso Cai, Mete Cek, Ekaterina Kulchavenya, Béla Köves, Kurt Naber, Tamara Perepanova, Peter Tenke, Björn Wullt, Florian Bogenhard, Truls Erik Bjerklund Johansen

Abstract

The Global Prevalence of Infections in Urology (GPIU) study is a worldwide-performed point prevalence study intended to create surveillance data on antibiotic resistance, type of urogenital infections, risk factors and data on antibiotic consumption, specifically in patients at urological departments with healthcare-associated urogenital infections (HAUTI). Investigators registered data through a web-based application (http://gpiu.esiu.org/). Data collection includes the practice and characteristics of the hospital and urology ward. On a certain day in November, each year, all urological patients present in the urological department at 8:00 a.m. are screened for HAUTI encompassing their full hospital course from admission to discharge. Apart from the GPIU main study, several side studies are taking place, dealing with transurethral resection of the prostate, prostate biopsy, as well as urosepsis. The GPIU study has been annually performed since 2003. Eight-hundred fifty-six urology units from 70 countries have participated so far, including 27,542 patients. A proxy for antibiotic consumption is reflected by the application rates used for antibiotic prophylaxis for urological interventions. Resistance rates of most uropathogens against antibiotics were high, especially with a note of multidrug resistance. The severity of HAUTI is also increasing, 25% being urosepsis in recent years.

Keywords: antibiotic administration; antibiotic resistance; healthcare-associated urinary tract infections; prostate biopsy; surveillance study; transurethral resection; urosepsis.

Figures

Figure 1
Figure 1
GPIU world map. Participating countries are marked in red.
Figure 2
Figure 2
Structure of the Global Prevalence of Infections in Urology (GPIU) application on the Internet.
Figure 3
Figure 3
Welcome page of the GPIU study.

References

    1. Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., Lynfield R., Maloney M., McAllister-Hollod L., Nadle J., et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 2014;370:1198–1208. doi: 10.1056/NEJMoa1306801.
    1. European Center for Disease Control and Prevention . Point Prevalence Survey of Healthcare Associated Infections and Antimicrobial Use in European Acute Care Hospitals, 2011–2012. European Center for Disease Control and Prevention; Stockholm, Sweden: 2013.
    1. European Section for Infetions in Urology (ESIU) Global Prevalence Study of Infections in Urology. 2015. [(accessed on 1 December 2015)]. Available online:
    1. Bjerklund Johansen T.E., Cek M., Naber K., Stratchounski L., Svendsen M.V., Tenke P., PEP and PEAP study investigators. European Society of Infections in Urology Prevalence of hospital-acquired urinary tract infections in urology departments. Eur. Urol. 2007;51:1100–1111. doi: 10.1016/j.eururo.2006.08.012. discussion 1112.
    1. Tandoğdu Z., Bartoletti R., Cai T., Çek M., Grabe M., Kulchavenya E., Köves B., Menon V., Naber K., Perepanova T., et al. Antimicrobial resistance in urosepsis: Outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. World J. Urol. 2015 doi: 10.1007/s00345-015-1722-1.
    1. Johansen T.E., Cek M., Naber K.G., Stratchounski L., Svendsen M.V., Tenke P. Hospital acquired urinary tract infections in urology departments: Pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int. J. Antimicrob. Agents. 2006;28:S91–S107. doi: 10.1016/j.ijantimicag.2006.05.005.
    1. Cek M., Tandogdu Z., Naber K., Tenke P., Wagenlehner F., van Oostrum E., Kristensen B., Bjerklund Johansen T.E., Global Prevalence Study of Infections in Urology Investigators Antibiotic prophylaxis in urology departments, 2005–2010. Eur. Urol. 2013;63:386–394. doi: 10.1016/j.eururo.2012.09.038.
    1. Tandogdu Z., Cek M., Wagenlehner F., Naber K., Tenke P., van Ostrum E., Johansen T.B. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J. Urol. 2014;32:791–801. doi: 10.1007/s00345-013-1154-8.
    1. Cek M., Tandogdu Z., Wagenlehner F., Tenke P., Naber K., Bjerklund-Johansen T.E. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003–2010. World J. Urol. 2014;32:1587–1594. doi: 10.1007/s00345-013-1218-9.
    1. Wagenlehner F.M., van Oostrum E., Tenke P., Tandogdu Z., Cek M., Grabe M., Wullt B., Pickard R., Naber K.G., Pilatz A., et al. Infective complications after prostate biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur. Urol. 2013;63:521–527. doi: 10.1016/j.eururo.2012.06.003.
    1. Bjerklund Johansen T.E. Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology. Int. J. Antimicrob. Agents. 2004;23:S30–S34. doi: 10.1016/j.ijantimicag.2003.09.003.
    1. GPIU STUDY 2015. [(accessed on 19 January 2016)]. Avaialble online:
    1. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control. 2008;36:309–332. doi: 10.1016/j.ajic.2008.03.002.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する